Amgen (AMGN) call put ratio 1 call to 1.26 puts after reporting Repatha data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amgen (AMGN) FOURIER Results 'Good Enough' - Cowen
March 17, 2017 11:23 AM EDTCowen analyst Eric Schmidt weighed in on Amgen (NASDAQ: AMGN) after the highly anticipated FOURIER CV outcomes data details were presented at ACC. The firm maintained an Outperform rating and price target of $209 on AMGN. He said the results were "good enough" to gradually transform... More
While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs
March 17, 2017 11:05 AM EDTGoldman Sachs analyst Terence Flynn weighed in on Amgen (NASDAQ: AMGN) after full data from Repatha (PCSK9) Ph3 cardiovascular outcomes trial, FOURIER, was presented.
Flynn commented, "In our view the primary endpoint effect is likely below investor expectations (hence why AMGN... More
